CytomX

$6.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.58%) Today

-$0.07 (-0.95%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CytomX and other stocks, options, and ETFs commission-free!

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. The listed name for CTMX is CytomX Therapeutics, Inc. Common Stock.

CEO

Sean A. McCarthy

Employees

158

Headquarters

South San Francisco, California

Founded

2010

Market Cap

298.21M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.65M

High Today

$7.34

Low Today

$6.77

Open Price

$7.04

Volume

1.94M

52 Week High

$15.44

52 Week Low

$3.60

Collections

Analyst Ratings

60%

of 10 ratings

Buy

60%

Hold

40%

Sell

CTMX Earnings

-$0.79

-$0.44

-$0.09

$0.26

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, After Hours